Aztreonam avibactam vs cefiderocol is an important clinical comparison in the treatment of difficult-to-treat Gram-negative infections. Both agents have activity against selected resistant pathogens, but they work through different mechanisms and have different clinical evidence bases.
Although both are used in the context of resistant infections, they work through different mechanisms and have different microbiological and clinical evidence bases.
A key point when comparing them is that there is currently no robust direct head-to-head clinical trial establishing whether aztreonam-avibactam or cefiderocol produces better overall clinical outcomes. The 2026 IDSA guidance also notes the absence of direct comparative clinical data for these agents in NDM-producing Enterobacterales.
Therefore, the most useful comparison focuses on their mechanisms, activity against specific organisms, clinical evidence, resistance considerations, approved indications and limitations of indirect comparisons.
Aztreonam Avibactam vs Cefiderocol: What Is Actually Being Compared?
Aztreonam-avibactam combines two components:
- Aztreonam, a monobactam antibiotic
- Avibactam, a β-lactamase inhibitor
Aztreonam has activity against Gram-negative bacteria and is stable against hydrolysis by metallo-β-lactamases (MBLs). However, MBL-producing organisms can also produce other β-lactamases, such as ESBLs and AmpC enzymes, that may compromise aztreonam activity. Avibactam helps inhibit several of these serine β-lactamases.
Cefiderocol is different. It is a siderophore cephalosporin designed to use bacterial iron-uptake pathways to enter Gram-negative bacteria. Once inside the bacterial cell, it binds penicillin-binding proteins (PBPs) and interferes with bacterial cell-wall synthesis.
So, although both agents can be relevant to resistant Gram-negative infections, they reach their antibacterial effect through different strategies.
Is There a Direct Clinical Trial Comparing Aztreonam Avibactam and Cefiderocol?
No robust direct randomized head-to-head clinical trial comparing aztreonam-avibactam with cefiderocol was identified.
This distinction is important.
Several clinical studies have evaluated aztreonam-avibactam, while separate studies have evaluated cefiderocol. These trials involved different patient populations, infection types, comparators and endpoints.
For example, the aztreonam-avibactam REVISIT study and cefiderocol CREDIBLE-CR study cannot simply be placed side by side and interpreted as a direct competition between the two drugs.
The 2026 IDSA guidance specifically states that direct comparative clinical data between aztreonam-avibactam and cefiderocol for NDM-producing Enterobacterales are unavailable.
Therefore, clinical cure percentages from separate trials should not be used to declare one agent superior to the other.
How Do Aztreonam Avibactam and Cefiderocol Work?
Aztreonam + avibactam mechanism
Aztreonam acts by binding to PBPs involved in bacterial cell-wall synthesis. One important feature is its stability against hydrolysis by class B metallo-β-lactamases.
However, MBL-producing organisms frequently carry additional serine β-lactamases. These enzymes can hydrolyze aztreonam and reduce its activity.
Avibactam inhibits several serine β-lactamases, including:
- Class A β-lactamases
- Class C β-lactamases
- Some class D β-lactamases
This creates a complementary mechanism:
Aztreonam provides the antibacterial activity, while avibactam protects it from susceptible serine β-lactamases.
This combination is particularly relevant when an organism produces an MBL together with other β-lactamases.
Cefiderocol mechanism
Cefiderocol uses a different approach.
It has a siderophore-like structure that allows it to bind iron and interact with bacterial iron-transport systems. The complex can then be transported into the bacterial cell through iron-uptake pathways.
Once inside the periplasmic space, cefiderocol binds PBPs and inhibits cell-wall synthesis.
Unlike aztreonam-avibactam, cefiderocol does not contain a β-lactamase inhibitor.
Its activity therefore depends on its intrinsic stability and ability to enter the bacterial cell through siderophore-mediated transport.
Aztreonam Avibactam vs Cefiderocol for MBL and NDM-Producing Enterobacterales
Metallo-β-lactamases such as NDM, VIM and IMP are important resistance mechanisms because they can hydrolyze many β-lactam antibiotics.
Aztreonam has a unique relationship with MBLs because it is not hydrolyzed by these enzymes. The challenge is that MBL-producing bacteria may simultaneously produce serine β-lactamases.
Avibactam can inhibit many of these additional enzymes.
Cefiderocol takes a different route. Its siderophore-mediated uptake and β-lactamase stability allow it to retain activity against many resistant Gram-negative organisms, including organisms carrying MBLs.
The 2026 IDSA guidance identifies both aztreonam-avibactam and cefiderocol as preferred options for NDM-producing Enterobacterales, while also noting that direct comparative clinical evidence is lacking.
What does recent laboratory evidence show?
Recent 2026 surveillance studies have reported different susceptibility patterns between the two agents.
One global study involving 490 genetically characterized MBL-producing Enterobacterales isolates reported:
- Aztreonam-avibactam: 100% susceptible using the cited EUCAST/FDA breakpoint
- Cefiderocol: 66.7% susceptible using EUCAST interpretation
- Cefiderocol: 90.8% susceptible using FDA breakpoint interpretation
Another global ATLAS analysis reported different susceptibility rates according to the carbapenemase genotype.
For example:
| Carbapenemase | Aztreonam-avibactam susceptible | Cefiderocol susceptible |
|---|---|---|
| NDM | 90.7% | 38.7% |
| NDM + OXA-48-like | 92.9% | 50.0% |
| IMP | 100% | 77.5% |
| VIM | 100% | 82.5% |
| KPC | 100% | 75.9% |
| OXA-48-like | 88.9% | 100% |
These results are in-vitro susceptibility findings, not clinical cure rates.
Breakpoint methodology, organism characteristics, resistance mechanisms and geographic distribution can influence susceptibility results. Therefore, laboratory findings should not be interpreted as proof that one treatment produces better clinical outcomes.
Aztreonam Avibactam vs Cefiderocol: Clinical Evidence
The clinical evidence for the two agents comes from different trials.
REVISIT: Aztreonam-avibactam
REVISIT was a Phase 3 study involving 422 patients:
- 282 received aztreonam-avibactam
- 140 received meropenem ± colistin
- Patients had complicated intra-abdominal infection or hospital-acquired/ventilator-associated pneumonia
Clinical cure was reported in:
- 68.4% with aztreonam-avibactam
- 65.7% with the comparator
The results provide clinical evidence for aztreonam-avibactam, but they should not be interpreted as a direct comparison with cefiderocol.
ASSEMBLE: MBL-producing infections
ASSEMBLE specifically investigated infections caused by MBL-producing Gram-negative bacteria.
The randomized population was very small:
- 12 patients received aztreonam-avibactam
- 3 received best available therapy
Clinical cure occurred in:
- 5/12 patients receiving aztreonam-avibactam
- 0/3 receiving best available therapy
Because the study population was extremely small, these findings are better regarded as supportive and exploratory evidence rather than definitive comparative evidence.
CREDIBLE-CR: Cefiderocol
CREDIBLE-CR was a Phase 3 study evaluating cefiderocol in serious infections caused by carbapenem-resistant Gram-negative bacteria.
The study included:
- 101 patients receiving cefiderocol
- 51 receiving best available therapy
The study included infections such as pneumonia, bloodstream infection/sepsis and complicated urinary tract infections.
In the microbiological intent-to-treat population, clinical cure was reported as:
- Pneumonia: 50% with cefiderocol vs 53% with best available therapy
- Bloodstream infection/sepsis: 43% vs 43%
The U.S. cefiderocol labeling also contains an important warning regarding increased all-cause mortality observed with cefiderocol compared with best available therapy in CREDIBLE-CR.
APEKS-NP: Cefiderocol
APEKS-NP evaluated cefiderocol for nosocomial pneumonia.
The Phase 3 study included 300 randomized patients:
- 148 cefiderocol
- 152 high-dose, extended-infusion meropenem
Day-14 mortality was:
- 12.4% with cefiderocol
- 11.6% with meropenem
The trial formally demonstrated non-inferiority of cefiderocol to high-dose meropenem for the studied population.
Again, this does not represent a head-to-head comparison with aztreonam-avibactam.
What About Cefiderocol in MBL Infections?
A pooled analysis of MBL-producing pathogen cases from CREDIBLE-CR and APEKS-NP included:
- 24 cefiderocol patients
- 10 comparator patients
Reported outcomes included:
- Clinical cure: 70.8% vs 40.0%
- Microbiological eradication: 58.3% vs 30.0%
- Day-28 mortality: 12.5% vs 50.0%
However, this was a small subgroup analysis.
It should therefore be interpreted as evidence regarding cefiderocol in MBL-associated infections, not as evidence that cefiderocol is superior or inferior to aztreonam-avibactam.
Spectrum Across Resistant Gram-Negative Bacteria
The comparison becomes more useful when the organism and resistance mechanism are considered separately.
| Organism / context | Aztreonam-avibactam | Cefiderocol |
|---|---|---|
| MBL Enterobacterales | Strong in-vitro activity; clinical data limited | Strong in-vitro activity; clinical data available but limited |
| NDM Enterobacterales | Preferred option in 2026 IDSA guidance | Preferred option in 2026 IDSA guidance |
| OXA-48 Enterobacterales | In-vitro activity; limited clinical data | In-vitro activity; limited clinical data |
| KPC Enterobacterales | Activity | Activity |
| MBL P. aeruginosa | Limited activity | Preferred option in 2026 IDSA guidance |
| Carbapenem-resistant P. aeruginosa | Activity is resistance-mechanism dependent | Established role in difficult-to-treat Gram-negative infections |
| Carbapenem-resistant A. baumannii | Not a primary ATM-AVI target | Important cefiderocol activity |
| Stenotrophomonas maltophilia | Not a primary ATM-AVI clinical target | Established cefiderocol activity |
This is why a simple “which antibiotic is better?” approach can be misleading. The organism, resistance mechanism and infection site all matter.
Aztreonam Avibactam vs Cefiderocol for Pseudomonas
The distinction is particularly important with Pseudomonas aeruginosa.
The 2026 IDSA guidance does not suggest aztreonam-avibactam for MBL-producing P. aeruginosa because its activity in this setting is limited.
Cefiderocol is identified as the preferred option for MBL-producing P. aeruginosa in the guidance.
One reason is that Pseudomonas resistance is not determined solely by β-lactamase production. Changes in permeability, efflux systems and other resistance mechanisms can significantly affect intracellular antibiotic exposure.
This illustrates why evidence from MBL-producing Enterobacterales cannot automatically be transferred to MBL-producing Pseudomonas.
What About Acinetobacter and Stenotrophomonas?
The two drugs also differ in their relevance to non-fermenting Gram-negative organisms.
Cefiderocol has established activity against difficult-to-treat organisms such as carbapenem-resistant Acinetobacter baumannii and Stenotrophomonas maltophilia in appropriate clinical contexts.
Aztreonam-avibactam is primarily discussed in the context of resistant Enterobacterales and has a more limited role against certain non-fermenters.
Therefore, the microbiological identity of the pathogen is an important factor when considering these agents.
Resistance Mechanisms
Neither antibiotic is completely protected from resistance.
Aztreonam-avibactam resistance
Potential mechanisms include:
- alterations in PBP3;
- AmpC/CMY-type β-lactamase changes;
- permeability changes;
- porin alterations;
- efflux mechanisms.
The 2026 IDSA guidance highlights combinations involving PBP3 alterations and CMY-type AmpC enzymes in some NDM-producing E. coli.
Cefiderocol resistance
Resistance to cefiderocol can involve:
- changes in siderophore or iron-transport pathways;
- PBP alterations;
- β-lactamase-related mechanisms;
- increased expression of certain β-lactamases, including NDM in specific settings.
Importantly, certain PBP3 alterations can affect the activity of both agents in particular NDM-producing E. coli backgrounds.
This means that resistance mechanisms should be considered at the individual isolate level rather than assuming that activity of one agent guarantees activity of the other.
FDA vs European Approved Indications
Regulatory indications are not identical across regions.
| Drug | United States | Europe |
|---|---|---|
| Aztreonam-avibactam | cIAI in adults with limited or no alternative treatment options, with metronidazole | cIAI, HAP/VAP, cUTI/pyelonephritis and certain aerobic Gram-negative infections with limited treatment options |
| Cefiderocol | cUTI including pyelonephritis; HABP/VABP | Infections due to aerobic Gram-negative organisms in adults with limited treatment options |
Because regulatory approvals can change, clinicians should consult the current prescribing information applicable to their jurisdiction.
Safety and Administration: Key Differences
Both drugs are administered intravenously and require consideration of renal function.
Aztreonam-avibactam is generally administered as a prolonged IV infusion, with dosing intervals adjusted according to renal function.
Cefiderocol is also administered by IV infusion and requires renal dose adjustment.
The safety profiles are not identical.
For aztreonam-avibactam, U.S. labeling identifies hepatic adverse reactions, anemia, diarrhea, hypokalemia and pyrexia among commonly reported adverse reactions.
For cefiderocol, U.S. labeling includes warnings concerning increased all-cause mortality observed in CREDIBLE-CR, hypersensitivity, C. difficile-associated diarrhea and CNS-related adverse reactions.
Detailed dosing and safety information should be reviewed separately rather than combining the two agents into a single dosing or safety framework.
For more information, see our guides on aztreonam-avibactam dosage and administration and aztreonam-avibactam renal dosing.
Why Clinical Trial Results Cannot Be Directly Compared
This is one of the most important points when evaluating aztreonam-avibactam versus cefiderocol.
It would be incorrect to compare:
REVISIT: 68.4% clinical cure
against
CREDIBLE-CR: 50% clinical cure
and conclude that aztreonam-avibactam is more effective.
The studies differed in:
- patient populations;
- infection types;
- resistance mechanisms;
- comparators;
- study design;
- endpoints;
- treatment settings;
- timing of outcome assessment.
In addition, REVISIT and CREDIBLE-CR were designed to answer different clinical questions.
The absence of a direct randomized comparison means that cross-trial percentages cannot establish comparative superiority.
What Does the 2026 IDSA Guidance Say?
The current IDSA guidance provides an organism- and resistance-specific framework.
For NDM-producing Enterobacterales, both aztreonam-avibactam and cefiderocol are identified as preferred treatment options.
Importantly, the guidance notes that direct comparative clinical evidence demonstrating superiority of one over the other is unavailable.
For MBL-producing Pseudomonas aeruginosa, cefiderocol has a preferred role, while aztreonam-avibactam is not suggested because of its limited activity in this setting.
This distinction reinforces an important principle:
The appropriate antimicrobial option depends on the pathogen, resistance mechanism, infection and available susceptibility information rather than on a universal ranking of the two drugs.
Frequently Asked Questions
Is aztreonam-avibactam the same as cefiderocol?
No. Aztreonam-avibactam combines a monobactam antibiotic with a β-lactamase inhibitor, while cefiderocol is a siderophore cephalosporin that uses bacterial iron-uptake pathways.
Is there a clinical trial directly comparing aztreonam-avibactam and cefiderocol?
No robust direct randomized head-to-head clinical trial was identified. The 2026 IDSA guidance also notes that direct comparative clinical data are unavailable for NDM-producing Enterobacterales.
How do aztreonam-avibactam and cefiderocol work differently?
Aztreonam targets PBPs and is protected by avibactam against susceptible serine β-lactamases. Cefiderocol uses siderophore-mediated iron uptake to enter Gram-negative bacteria before binding PBPs.
Are both drugs active against NDM-producing bacteria?
Both have activity against NDM-producing Enterobacterales, and both are listed as preferred options in the 2026 IDSA guidance. Individual susceptibility testing and clinical context remain important.
How do they compare for MBL-producing Enterobacterales?
Both demonstrate activity against MBL-producing Enterobacterales. Recent laboratory studies have reported different susceptibility patterns, but laboratory susceptibility results should not be interpreted as direct clinical superiority.
What did the REVISIT trial show?
REVISIT evaluated aztreonam-avibactam in complicated intra-abdominal infections and hospital-acquired/ventilator-associated pneumonia. Clinical cure was 68.4% with aztreonam-avibactam versus 65.7% with the comparator group.
What did the ASSEMBLE trial show?
ASSEMBLE evaluated aztreonam-avibactam in MBL-producing infections. The study was very small, with 12 patients receiving aztreonam-avibactam and 3 receiving best available therapy, so its findings are considered supportive rather than definitive.
What did CREDIBLE-CR show for cefiderocol?
CREDIBLE-CR evaluated cefiderocol in serious carbapenem-resistant Gram-negative infections. Outcomes varied by infection type, and the U.S. label includes a warning regarding increased all-cause mortality observed with cefiderocol versus best available therapy.
What does IDSA 2026 say about aztreonam-avibactam and cefiderocol?
For NDM-producing Enterobacterales, both are identified as preferred options, while direct comparative clinical evidence is lacking. For MBL-producing P. aeruginosa, cefiderocol has the preferred role in the guidance.
Why can’t clinical cure rates from different trials be directly compared?
Because separate trials may have different patient populations, pathogens, infection types, comparators, endpoints and study designs. Cross-trial percentages therefore cannot establish that one antibiotic is clinically superior to another.
Conclusion
Aztreonam-avibactam and cefiderocol are important options in the management of selected difficult-to-treat Gram-negative infections, but they should not be viewed as interchangeable antibiotics.
Their mechanisms are fundamentally different. Aztreonam-avibactam combines aztreonam’s activity against Gram-negative bacteria with avibactam’s inhibition of several serine β-lactamases, while cefiderocol uses siderophore-mediated uptake to reach its bacterial targets.
For NDM-producing Enterobacterales, the 2026 IDSA guidance recognizes both agents as preferred options, while acknowledging the lack of direct comparative clinical evidence. Their roles differ in other organisms, particularly MBL-producing Pseudomonas aeruginosa and other difficult-to-treat non-fermenters.
Most importantly, there is currently no robust direct head-to-head clinical trial establishing overall superiority of aztreonam-avibactam versus cefiderocol. Laboratory susceptibility studies and separate clinical trials provide useful evidence, but they should be interpreted according to the organism, resistance mechanism, infection and study context.
For clinicians and researchers, the most meaningful comparison is therefore not simply “which drug is better,” but which evidence applies to the specific pathogen and resistance mechanism being treated.
Medical note: This article is for educational and scientific information. Selection and administration of antimicrobial therapy should be based on the patient’s clinical condition, microbiological results, local resistance patterns, current prescribing information and specialist clinical judgment.